Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Neuroblastoma 1

Interventions

Cyclophosphamide 3naxitamab 2fludarabine phosphate 2fludarabine 2dinutuximab 2Topotecan 2Granulocyte-Macrophage Colony-Stimulating Factor 2Colony-Stimulating Factors 2sargramostim 1iberdomide 1eliglustat 1Vorinostat 1Thiotepa 1Tacrolimus 1Mycophenolic Acid 1Methotrexate 1Melphalan 1Magnetic Resonance Spectroscopy 1Isotretinoin 1Cyclosporine 1Busulfan 1Biopsy 1Antilymphocyte Serum 13-Iodobenzylguanidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Neuroblastoma × eliglustat × Clear all
NCT07090538 2025-07-29

GSL Synthetase Inhibitor Plus GM-CSF and/ or Immune Checkpoint Inhibitor in Previously Treated High-Risk Neuroblastoma.

Chinese PLA General Hospital

Phase EARLY_PHASE1 Not yet recruiting
10 enrolled
CNS

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡